{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["193(6)"],"submitter":["Mistry K"],"funding":["Cancer Research UK"],"pubmed_abstract":["<h4>Background</h4>Inadequacy of testing for melanoma BRAF status results in delayed access to systemic therapy. BRAF mutations and their association with patient/tumour characteristics and survival is poorly understood.<h4>Objectives</h4>To report national data from England on the frequency of molecular BRAF testing; the association of patient/tumour characteristics with BRAF mutations; and the treatment and survival of patients with BRAF mutations.<h4>Methods</h4>This national retrospective cohort study identified all new melanomas and molecular BRAF testing in England diagnosed from 2016 to 2021 using population-based data from the National Disease Registration Service. Multivariate logistic regression determined the association between BRAF testing with patient/tumour characteristics a"],"journal":["The British journal of dermatology"],"pagination":["1146-1154"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12626136"],"repository":["biostudies-literature"],"pubmed_title":["A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021."],"pmcid":["PMC12626136"],"pubmed_authors":["Bright C","McRonald F","Jeffrey P","Pethick J","Taylor S","Kennedy O","Richardson K","Lavelle K","Mistry K","Ragan J","Craig P","Lorigan P","Venables ZC","Levell NJ","Vernon S","Karponis D","Hardy S"],"additional_accession":[]},"is_claimable":false,"name":"A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021.","description":"<h4>Background</h4>Inadequacy of testing for melanoma BRAF status results in delayed access to systemic therapy. BRAF mutations and their association with patient/tumour characteristics and survival is poorly understood.<h4>Objectives</h4>To report national data from England on the frequency of molecular BRAF testing; the association of patient/tumour characteristics with BRAF mutations; and the treatment and survival of patients with BRAF mutations.<h4>Methods</h4>This national retrospective cohort study identified all new melanomas and molecular BRAF testing in England diagnosed from 2016 to 2021 using population-based data from the National Disease Registration Service. Multivariate logistic regression determined the association between BRAF testing with patient/tumour characteristics a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T16:04:34.465Z","creation":"2026-05-18T03:12:44.395Z"},"accession":"S-EPMC12626136","cross_references":{"pubmed":["40902091"],"doi":["10.1093/bjd/ljaf351"]}}